Physician profile
Mark Daniel
NPI 1700883659
$11,470.49
in general payments reported to CMS, 2019-2025
47 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $980 · 2021: $2,155 · 2022: $1,712 · 2023: $1,792 · 2024: $1,915 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,287.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,166.52 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,069.22 | 2020-2025 | Vraylar, Dalvance, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $916.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boston Scientific Corporation | $751.78 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $663.48 | 2019-2025 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $569.58 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Lilly USA, LLC | $563.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $506.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $480.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $430.60 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $393.76 | 2019-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $368.22 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $361.96 | 2019-2025 | |
| Shield Therapeutics INC | $302.37 | 2023-2024 | Accrufer |
| Amgen INC. | $300.15 | 2019-2025 | Repatha, Otezla, Otezla |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $241.81 | 2019-2022 | |
| Axsome Therapeutics, INC. | $197.61 | 2024-2025 | Auvelity |
| Corcept Therapeutics | $190.69 | 2022-2025 | Korlym |
| Lundbeck LLC | $163.47 | 2022-2025 | Rexulti, Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.90 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $156.69 | 2023-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $145.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $127.26 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $125.25 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $124.30 | 2019-2023 | Livalo, Seglentis |
| Esperion Therapeutics, INC. | $116.31 | 2020-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $94.69 | 2019-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $92.87 | 2022-2024 | Quviviq |
| Merck Sharp & Dohme LLC | $83.93 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Nestle Healthcare Nutrition INC. | $83.53 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $61.81 | 2023-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company Ltd. | $59.69 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.06 | 2021-2022 | |
| Biogen, INC. | $50.12 | 2021 | |
| Dexcom, INC. | $48.25 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $37.79 | 2024 | Freestyle Libre 3 |
| Genentech USA, INC. | $33.08 | 2019-2020 | |
| Allergan, INC. | $33.04 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $25.96 | 2024 | Fanapt |
| Mylan Specialty L.P. | $17.79 | 2024 | Yupelri |
| Horizon Therapeutics Plc | $17.39 | 2021 | |
| Cranial Technologies, INC | $16.80 | 2024 | Doc Band |
| Hikma Pharmaceuticals USA | $15.14 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.14 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $15.12 | 2024 | Uptravi, Opsumit |
| Biohaven Pharmaceuticals, INC. | $11.70 | 2021 | |
| Eisai INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.